Pharma lagged the risk-on tape with only muted moves — the peptide and packaging names tied to GLP-1 demand firmed, Bachem +4.3% the leader, while Baxter −3.2% extended its sterile-injectables overhang.

On a session that rewarded chips and satellites, the supply-chain pharma basket was a defensive laggard, and its moves were modest. Bachem (BCHMY) was the top gainer, up 4.3% to $10.15 — a thin ADR line with no single dated catalyst behind it, but a coherent read on the peptides-oligos chokepoint. Bachem is the Swiss peptide CDMO scaling New Building K in Bubendorf against 35-45% local-currency sales-growth guidance for 2026, and its bottleneck sits directly upstream of the GLP-1 wave: the specialized peptide-API capacity that Wegovy- and Zepbound-class drugs depend on. The same thread lifted the packaging side — Stevanato (STVN) rose 4.1% to $18.07, whose EZ-fill vials, cartridges and Nexa syringes carry those GLP-1 doses, with GLP-1s already near a fifth of its revenue.

Baxter (BAX) was the laggard, down 3.2% to $21.32, extending a long slide rather than reacting to a fresh Tuesday catalyst. Baxter anchors the sterile-injectables-shortages chokepoint — its North Cove, NC plant produced roughly 60% of US IV-fluid supply before Hurricane Helene flooded it in 2024 — but the stock trades on its own operational overhangs: soft organic sales, compressed margins, and the unresolved Novum LVP infusion-pump regulatory hold that continues to block shipments. On a day capital rotated toward risk, the structurally challenged names in the group were left behind.

Elsewhere the moves were small and instrument-led. On the bioprocessing chokepoint, Sartorius's ADR (SOAGY) added 2.9% to $52.41, while the lab-and-analytics names firmed modestly — Waters (WAT) +1.7% to $375.04, Mettler-Toledo (MTD) +1.5% to $1,277.51, West Pharmaceutical (WST) +1.2% to $359.00. The notable red mark among the majors was Eli Lilly (LLY), down 2.5% to $1,199.43; as the GLP-1 demand engine sitting downstream of the peptide and packaging chokepoints, its slip capped what was otherwise a quietly constructive session for the supply chain that feeds it.

The pharma calendar's defining event is regulatory: the Section 232 pharmaceutical tariffs — up to 100% on patented pharma imports — are set to take effect July 31, the single largest swing factor for API-reshoring and CDMO capacity. Earnings then cluster into late July: Lonza's H1 on July 22, Sartorius on July 23, Bachem's own H1 on July 24, and Baxter's Q2 around July 30, with a Novo Nordisk FDA fill-finish classification decision expected July 23 — each a read on whether the shortage-and-reshoring thesis is tightening.